Regulatory flexibility and early conversations allowed COVID-19 vaccine candidates to move to market quickly and should remain in place as next generation products enter the development process, sponsors said.
Angela Hwang, group president of Pfizer Inc.’s Biopharmaceuticals Group, said “the fit-for-purpose way of looking at what is the issue in hand and what is the kind of approval that we need” was a key advantage that allowed its vaccine to move quickly
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?